Related Experiment Video

Updated: Sep 25, 2026

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
09:25

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations

Published on: January 10, 2015

Decreasing smoking behaviour and risk through CYP2A6 inhibition

Edward M Sellers1, Rachel F Tyndale, Leona C Fernandes

  • 1Department of Pharmacology, Psychiatry, Medicine University of Toronto, Ontario M5T 3A9, Toronto, Canada. e.sellers@ventana-crc.com

Drug Discovery Today
|June 24, 2003
PubMed

Insights

Novel treatments for tobacco dependence are emerging, focusing on manipulating nicotine metabolism via cytochrome P450 2A6 (CYP2A6). Understanding CYP2A6 activity and genetic variations may lead to improved smoking cessation outcomes and reduced cancer risk.

Area of Science:

  • Pharmacology and Toxicology
  • Genetics
  • Drug Development

Background:

  • Tobacco dependence poses significant health and economic burdens.
  • Current treatments for nicotine addiction have limitations, necessitating novel approaches.
  • Drug development for smoking cessation requires innovative strategies.

Purpose of the Study:

  • To review current tobacco dependence treatments.
  • To explore new treatment strategies targeting nicotine metabolism.
  • To discuss drug development and proof-of-concept models for novel therapies.

Main Methods:

  • Review of existing literature on tobacco dependence treatments.
  • Analysis of recent discoveries in drug development for smoking cessation.
  • Focus on cytochrome P450 2A6 (CYP2A6) activity and its role in nicotine metabolism.

Main Results:

  • Cytochrome P450 2A6 (CYP2A6) plays a key role in nicotine metabolism.
  • CYP2A6 genetic variations are associated with reduced risk of tobacco dependence and smoking-related cancers.
  • Strategies manipulating CYP2A6 activity show promise for novel treatments.

Conclusions:

  • Targeting CYP2A6 offers a promising avenue for developing new tobacco dependence treatments.
  • Understanding CYP2A6 polymorphisms can inform personalized smoking cessation strategies.
  • Further research and proof-of-concept studies are crucial for advancing these novel therapies.

More Related Videos

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke09:50

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke

Published on: February 12, 2015

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...